Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Renal Protection in SIRS
NCT05946122Phase 1Unknown
- Sponsor
- Minia University
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atorvastatin in Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Minia University. Primary endpoint: Acute kidney injury at 1 week. Status: unknown.
02
Drugs
atorvastatin
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT05946122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946122.